The phase III JAVELIN Renal 101 trial reported that patients with PD-L1 positive, advanced RCC receiving first-line avelumab plus axitinib had significantly better outcomes than those treated with sunitinib. This evidence concerns the gene CD274 and renal cell adenocarcinoma.